Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No GIST-type c-kit gain of function mutations in neuroblastic tumours.

Journal of clinical pathology - 1 Jul 2005

Korja M, Finne J, Salmi T T, Haapasalo H, Tanner M, Isola J

Abstract excerpt

AIMS: Neuroblastic tumours (NTs) have been shown to respond to imatinib treatment in vivo and in vitro, possibly via inactivating the c-kit receptor. The purpose of this study was to identify gastrointestinal stromal tumour (GIST)-type c-kit gene associated mutations in exons 9, 11, 13, and 17 in NTs to recognise a subset of tumours that would probably respond to imatinib treatment. METHODS: Expression of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chromatography, High Pressure Liquid
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Neuroblastoma

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 15976348
DOI: 10.1136/jcp.2004.024331
PMCID: PMC1770714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No GIST-type c-kit gain of function mutations in neuroblastic tumours.PMID 15976348Read ↗

Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.Semantic proximity Read ↗

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.Semantic proximity Read ↗

C-kit gene mutation in human gastrointestinal stromal tumors.Semantic proximity Read ↗

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.Semantic proximity Read ↗

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.Semantic proximity Read ↗

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.Semantic proximity Read ↗

Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.Semantic proximity Read ↗

The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.Semantic proximity Read ↗

Molecular Alterations of <i>KIT</i> Oncogene in GliomasSemantic proximity Read ↗

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.Semantic proximity Read ↗

Alterations of the c-kit gene in testicular germ cell tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.